Format

Send to

Choose Destination
Future Med Chem. 2012 Apr;4(5):651-60. doi: 10.4155/fmc.12.17.

Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors.

Author information

1
Department of Medicinal Chemistry, R&I iMED, AstraZeneca R&D, Pepparedsleden 1, SE-431 83, Mölndal, Sweden. peter.sjo@astrazeneca.com

Abstract

Due to its implication in pathologies of prevalent diseases such as chronic obstructive pulmonary disease, fibrosis, bronchiectasis and ARDS, the serine protease, human neutrophil elastase, has been in focus for drug-development efforts over the last two decades. In recent years, continued efforts to identify and optimize novel mechanism-based inhibitors have led to a number of new inhibitors being reported. These compounds show promising potency and selectivity profiles, although their use is still limited by their inherent stability. Recently, two novel classes of potent and selective, synthetic, nonelectrophilic human neutrophil elastase inhibitors that display improved stability and overall drug-like properties have been reported. The most advanced compound from these classes, AZD9668, has been reported to show significant effects on relevant biomarkers in bronchiectasis and cystic fibrosis patient populations.

PMID:
22458683
DOI:
10.4155/fmc.12.17
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center